Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 5, 1998, Pages 1139-1145

  Gnann Jr , John W ^a   Crumpacker, Clyde S ^b   Lalezari, Jacob P ^c,m   Smith, Jean A ^d   Tyring, Stephen K ^e   Baum, Kenneth F ^f   Borucki, Michael J ^g   Joseph, W Patrick ^h   Mertz, Gregory J ⁱ   Steigbigel, Roy T ^j   Cloud, Gretchen A ^k   Soong, Seng Jaw ^k   Sherrill, Lanette C ^k   DeHertogh, Deborah A ^l   Whitley, Richard J ⁿ  

^a University of Alabama at Birmingham   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h Infectious Diseases Medical Group   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j STONY BROOK UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

^m Quest Clinical Research   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; SORIVUDINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SKIN DEFECT; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0031981859     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.5.1139     Document Type: Article

References (19)

1. Balfour, H. H., B. Bean, O. L. Laskin, R. F. Ambinder, J. D. Meyers, J. C. Wade, J. A. Zaia, D. Aeppli, L. E. Kirk, A. C. Segreti, R. E. Keeney, and Burroughs Wellcome Collaborative Antiviral Study Group. 1983. Acyclovir halts progression of herpes zoster in immunocompromised patients. N. Engl. J. Med. 308:1448-1453.
2. Bodsworth, N. J., F. Boag, D. Burdge, M. Généreux, J. C. C. Borleffs, B. A. Evans, J. Modai, R. Colebunders, J. Thomis, and the Multinational Sorivudine Study Group. 1997. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. J. Infect. Dis. 176:103-111.
3. Buchbinder, S. P., M. H. Kate, N. A. Hessol, J. Y. Lin, P. M. O'Malley, R. Underwood, and S. D. Holberg. 1992. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 166:1153-1156.
4. Descamps, J., R. K. Sehgal, E. DeClereq, and S. Allauden. 1982. Inhibitory effect of E-5-(2-bromovinyl)-1-β-D-arabinofuranusyluracil on herpes simplex virus replication and DNA synthesis. J. Virol. 43:332-336.
5. Desgranges, C., G. Razaka, E. DeClerq, P. Herdewijn, J. Balzarini, F. Drouillet, and H. Bricaud. 1986. Effect of E-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46:1094-1101.
6. Glesby, M. J., R. D. Moore, and R. E. Chaisson. 1995. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin. Infect. Dis. 21:370-375.
7. Machida, H. 1986. Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs. Antimicrob. Agents Chemother. 29:524-526.
8. Niimura, M. 1990. A double-blind clinical study in patients with herpes zoster to establish YN-72(Brovavir) dose, p. 267-275. In C. Lopez, R. Mori, B. Roizman, and R. J. Whitley (ed.), Immunobiology and prophylaxis of human herpesvirus infections. Plenum Press, New York, N.Y.
9. O'Brien, P. C., and T. R. Fleming. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549-556.
10. Rogues, A.-M., M. Dupon, J. Ladner, J.-M. Ragnaud, J.-L. Pellegrin, F. Dabis, and Groupe D'Epidemiologie Clinque du SIDA en Aquitaine. 1993. Herpes zoster and human immunodeficiency virus infection: a cohort study of 101 co-infected patients. J. Infect. Dis. 168:245.
11. Sherman, J., A. Devault, C. Natarajan, J. Harkins, B. Hedden, B. Stouffer, D. Whigan, L. Kassalow, D. Grasela, A. Surgerman, and K. Reilly. 1990. SQ 32,756 (BV-araU): characteristics and pharmacokinetics in healthy young and elderly male volunteers, abstr. 1103, p. 270. In Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
12. Sherman, J., L. Kassalow, B. J. Harkins, B. J. Suites, B. Stougger, D. Whigan, A. A. Shugerman, and S. A. Smith. 1990. SQ32,756 (BV-araU): characteristics and pharmacokinetic evaluation in healthy male volunteers. Antivir. Res. 13(Suppl. 1):100.
13. Shigeta, S., T. Yokota, T. Iwabuchi, M. Baba, K. Konno, M. Ogata, and E. DeClercq. 1983. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J. Infect. Dis. 147:576-584.
14. Sullivan, M., D. Skiest, D. Signs, C. Young, and the Famciclovir Herpes Zoster in HIV Study Group. 1997. Famciclovir in the management of acute herpes zoster (HZ) in the HIV-positive patients, abstr. 704. In Fourth Conference on Retroviruses and Opportunistic Infections.
15. Swinbanks, D. 1994. Deaths bring clinical trials under scrutiny in Japan. Nature 369:697.
16. Wallace, M. R., C. J. Chamberlin, M. H. Sawyer, A. M. Arvin, J. Harkins, A. LaRocco, M. W. Colopy, W. A. Bowler, and E. C. Oldfield. 1996. Treatment of adult varicella with sorivudine: a randomized placebo-controlled trial. J. Infect. Dis. 174:249-255.
17. Whitley, R. J., J. W. Gnann, D. Hinthorn, C. Liu, R. B. Pollard, F. Hayden, G. J. Mertz, M. Oxman, S. J. Soong, and the NIAID Collaborative Antiviral Study Group. 1992. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J. Infect. Dis. 165:450-455.
18. Yawata, M. 1993. Deaths due to drug interaction. Lancet 342:1166.
19. Yokata, T., K. Kono, S. Mori, S. Shigeta, M. Kumangai, Y. Watanabe, and H. Machida. 1989. Mechanism of selective inhibition of varicella-zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Mol. Pharmacol. 36:312-316.